SCHEMBL5564480

SCHEMBL5564480

Cc1ccc2ncnc(Nc3ccc(Br)cc3)c2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.76
KDM4E B2RXH2 3/20 0.76
HTT P42858 2/20 0.76
NCOA1 Q15788 2/20 0.72
NCOA3 Q9Y6Q9 2/20 0.72
MAPT P10636 3/20 0.72
LMNA P02545 2/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
ALDH1A1 P00352 2/20 0.65
ALK Q9UM73 1/20 0.65
MEN1 O00255 1/20 0.65
GLA P06280 1/20 0.65
KMT2A Q03164 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
NPC1 O15118 2/20 0.64
EGFR P00533 6/20 0.62
KDR P35968 1/20 0.62
HPGD P15428 1/20 0.62
POLB P06746 1/20 0.60
RAB9A P51151 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13621688 0.91 KDM4E (0.74) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL5570037 0.87 HTT (0.74) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL5568874 0.87 HTT (0.74) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL5569927 0.87 KDM4E (0.74) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL2101381 0.86 HTT (1.00) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL5564456 0.86 MAPK1 (0.82) MAPK1KDM4EHTTMAPTMEN1
SCHEMBL5570076 0.84 HTT (0.70) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL15503743 0.84 NCOA1 (1.00) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL5568430 0.84 HTT (1.00) MAPK1KDM4EHTTNCOA1NCOA3
SCHEMBL4586685 0.83 EGFR (0.75) KDM4ENCOA1NCOA3LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT MAPK1 1019/4885KDM4E 1004/4885HTT 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.